On the heels of news that drug companies have overtaken defense as government fraudsters, Dey Pharma has agreed to pay $280 million to settle a Justice Department lawsuit over Medicare and Medicaid ...

Dey Pharma, a subsidiary of Mylan Inc., has agreed to pay $280 million to the federal government to settle allegations that it had violated the False Claims Act by engaging in a scheme to report ...

BASKING RIDGE, N.J., Jan. 20, 2011 /PRNewswire/ -- Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), launched MyEpiPen App for iPhone and iPod touch and ...

Dey Pharma — which was involved in the suit prior to begin acquired by Mylan from Merck KGaA in 2007 — said that it agreed to pay $280 million to the DoJ in exchange for a release of claims ...

(Nasdaq: MYL) today announced that it plans to change the name of its fully integrated branded specialty pharmaceutical business from Dey Pharma to Mylan Specialty. Mylan CEO Heather Bresch said ...

In a late-Monday statement, the former unit, Dey Pharma LP, Basking Ridge, N.J., said the September 2006 lawsuit by the Justice agency concerned Medicare and Medicaid reimbursements that the U.S ...

The companies are: Actavis Inc., Boehringer-Ingelheim, Dey Pharma, GlaxoSmithKline and Schering-Plough Corp. Attorney General Buddy Caldwell The settlements, which range from $3 million to $10 ...

In 2007, Mylan's unit Dey Pharma sued Sunovion alleging its drug Brovana infringes seven of Dey's patents. The U.S. Food and Drug Administration had approved Brovana in 2006 for the treatment of ...